Vir Biotechnology Inc Forecast, price target & analysts
Vir Biotechnology Inc Target price 2025 - Analyst rating & recommendation
Vir Biotechnology Inc Classifications & Recommendation:
Vir Biotechnology Inc Price Target
| Target Price | $17.88 |
| Price | $4.73 |
| Potential |
277.91%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Vir Biotechnology Inc 2026 .
The average Vir Biotechnology Inc target price is $17.88.
This is
277.91%
register free of charge
$31.00
555.39%
register free of charge
$12.00
153.70%
register free of charge
|
|
| A rating was issued by 9 analysts: 7 Analysts recommend Vir Biotechnology Inc to buy, 2 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Vir Biotechnology Inc stock has an average upside potential 2026 of
277.91%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 74.21 | 16.92 |
| 13.89% | 77.20% | |
| EBITDA Margin | -743.66% | -2,960.59% |
| 6.28% | 331.76% | |
| Net Margin | -712.53% | -2,679.63% |
| 3.10% | 276.07% |
8 Analysts have issued a sales forecast Vir Biotechnology Inc 2025 . The average Vir Biotechnology Inc sales estimate is
This results in the following potential growth metrics:
5 Analysts have issued an Vir Biotechnology Inc EBITDA forecast 2025. The average Vir Biotechnology Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
6 Vir Biotechnology Inc Analysts have issued a net profit forecast 2025. The average Vir Biotechnology Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -3.83 | -3.28 |
| 16.56% | 14.36% | |
| P/E | negative | |
| EV/Sales | negative |
6 Analysts have issued a Vir Biotechnology Inc forecast for earnings per share. The average Vir Biotechnology Inc EPS is
This results in the following potential growth metrics and future valuations:
Vir Biotechnology Inc...
Current Vir Biotechnology Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Needham |
Locked
➜
Locked
|
Locked | May 12 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Barclays |
Locked
➜
Locked
|
Locked | Feb 28 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 27 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Jan 31 2025 |
| Leerink Partners |
Locked
➜
Locked
|
Locked | Jan 13 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Needham:
Locked
➜
Locked
|
May 12 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Barclays:
Locked
➜
Locked
|
Feb 28 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 27 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Jan 31 2025 |
|
Locked
Leerink Partners:
Locked
➜
Locked
|
Jan 13 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
